• Clarity Pharmaceuticals receives $9.8 million R&D tax incentive refund
• Refund recognises significant eligible Australian R&D in radiopharmaceutical field
• Funding will further development of Clarity's Targeted Copper Theranostic (TCT) platform

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has received a Research and Development (R&D) Tax Incentive refund of $9,759,467 from the Australian Federal Government's R&D Tax Incentive program. The refund recognises the significant eligible Australian R&D undertaken by Clarity in the radiopharmaceutical field during the financial year ended 30 June 2025. The R&D tax incentive program encourages companies to invest in R&D activities by providing a refundable tax offset of up to 48.5% of the eligible activities. The $9.8 million refund will provide additional funding to further the development of Clarity's Targeted Copper Theranostic (TCT) platform of products for various cancer indications. Clarity's Executive Chairperson, Dr Alan Taylor, commented that the refund reflects the company's commitment to continuous investment in research and development, and that the non-dilutive funding will extend Clarity's cash runway and enable the exploration of novel targets in indications with high unmet needs.